(Q41743362)

English

Combinations of reverse transcriptase, protease, and integrase inhibitors can be synergistic in vitro against drug-sensitive and RT inhibitor-resistant molecular clones of HIV-1.

scientific article published on June 2000

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

Combinations of reverse transcriptase, protease, and integrase inhibitors can be synergistic in vitro against drug-sensitive and RT inhibitor-resistant molecular clones of HIV-1. (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

author name string

Beale KK

1

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

Robinson WE Jr

2

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

publication date

1 June 2000

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

Antiviral Research

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

46

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

223-232

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900083-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900083-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination therapy for infection due to human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900083-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900083-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Generalized Equations for the Analysis of Inhibitions of Michaelis-Menten and Higher-Order Kinetic Systems with Two or More Mutually Exclusive and Nonexclusive Inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900083-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Current use of anti-HIV drugs in AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900083-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900083-8

7 January 2021

based on heuristic

inferred from DOI database lookup

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900083-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900083-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900083-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Human immunodeficiency virus type 1 pol gene mutations in an AIDS patient treated with multiple antiretroviral drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900083-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Persistence of HIV-1 Transcription in Peripheral-Blood Mononuclear Cells in Patients Receiving Potent Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900083-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900083-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900083-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900083-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900083-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900083-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900083-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2',3'-dideoxycytidine, or recombinant interferon-alpha A against zidovudine-sensitive or -resistant HIV-1 in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900083-8

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro inhibition of human immunodeficiency virus (HIV) type 1 replication by C2 symmetry-based HIV protease inhibitors as single agents or in combinations

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900083-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Structure-activity relationships: analogues of the dicaffeoylquinic and dicaffeoyltartaric acids as potent inhibitors of human immunodeficiency virus type 1 integrase and replication

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900083-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Resistance to the anti-human immunodeficiency virus type 1 compound L-chicoric acid results from a single mutation at amino acid 140 of integrase

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900083-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900083-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Chicoric acid analogues as HIV-1 integrase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900083-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900083-8

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro evaluation of mismatched double-stranded RNA (ampligen) for combination therapy in the treatment of acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900083-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900083-8

7 January 2021

based on heuristic

inferred from DOI database lookup

BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900083-8

7 January 2021

based on heuristic

inferred from DOI database lookup

L-chicoric acid, an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase, improves on the in vitro anti-HIV-1 effect of Zidovudine plus a protease inhibitor (AG1350).

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900083-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibitors of HIV-1 replication [corrected; erratum to be published] that inhibit HIV integrase

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900083-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Characterization of HIV-1 protease mutants: random, directed, selected

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900083-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900083-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900083-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900083-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Irreversible inhibition of human immunodeficiency virus type 1 integrase by dicaffeoylquinic acids

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900083-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Drug combinations and effect parameters of zidovudine, stavudine, and nevirapine in standardized drug-sensitive and resistant HIV type 1 strains

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900083-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0166-3542(00)00083-8

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41743362&oldid=2131715337"